May 12th 2025
Across various classes, the researchers identified a model that, when coupled with appropriate data augmentation and optimization partner, may help aid in the detection of skin cancer.
What’s Next in Health Care? Panelists Highlight Data, Partnerships Post-COVID-19
June 24th 2022Panelists of an AHIP 2022 session discussed how future policy, infrastructure, and investment strategies in public health will reinforce the efforts already made during the pandemic, with partnerships and engagement key to optimize innovation.
Read More
Switching Among Infliximab Biosimilars Effective and Well Tolerated, Research Finds
June 24th 2022Among a real-world cohort of patients, switching between infliximab biosimilars was effective and well tolerated, although retention was higher among those who had initially started on the originator product.
Read More
Supreme Court Overturns Roe v Wade, Turning Issue Back to States
June 24th 2022Reversing a landmark precedent, the Supreme Court voted Friday to overturn 1973’s Roe v Wade decision that guaranteed American women the constitutional right to an abortion, and at least 1 justice suggested that other precedents, such as the right to birth control, be reversed as well.
Read More
Meningococcal Vaccine Uptake Lagging Among People Living With HIV
June 23rd 2022The findings of this study, which used insurance claims data for patients 2 years and older to determine rates of meningococcal A, C, W, Y vaccine uptake, points to the need for more education, the authors said.
Read More
Biosimilar Utilization Increased During the OCM and Generated Savings
June 23rd 2022Abstracts presented at the American Society of Clinical Oncology Annual Meeting evaluated biosimilar use in practices participating in the Oncology Care Model (OCM) and estimated the savings as a result of substituting these agents for more expensive reference products.
Read More
There Is More to Blame Than Tech for T1D Outcomes Disparities, Investigators Argue
June 21st 2022Investigators from the Pediatric Diabetes Center at Hassenfeld Children’s Hospital at NYU Langone investigated outcomes disparities as they related to diabetes technology use among youth living with type 1 diabetes (T1D).
Read More
Standard-of-Care Treatments Insufficient in Improving QOL for Patients With Multiple Myeloma
June 19th 2022Patients with multiple myeloma frequently relapse and experience deteriorating quality of life, according to findings from the LocoMMotion study, which also reported that specific patient and disease characteristics are associated with poor efficacy outcomes.
Read More
Sacubitril/Valsartan Safe, Effective Among CHF Patients on Maintenance Hemodialysis
June 18th 2022Outcomes in this new study, conducted among patients with chronic heart failure (CHF) on maintenance dialysis and receiving sacubitril/valsartan, were evaluated as they pertained to heart function and blood pressure.
Read More
Caregiver Contributions in Heart Failure Require Further Study
June 16th 2022The primary outcomes of this secondary analysis of the MOTIVATE-HF study were improvement in caregiver self-efficacy while caring for patients living with heart failure and caregiver contributions to self-care for these patients following motivational interviewing.
Read More
Dr Mazyar Shadman Highlights the Challenges of Subgroup Analysis When Trials Lack Diversity
June 16th 2022Increased diversity in clinical trials remains an unmet need, and in the new SEQUOIA trial, the majority of patients being White males meant researchers could not do a subgroup analysis looking at outcomes for specific races, age groups or genders, said Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Research Center.
Watch
Survivors of Childhood Cancer More Likely to Be Undertreated for CVD Risk Factors
June 11th 2022Despite a greater risk of cardiovascular disease (CVD) due to exposure to chemotherapy and/or radiation, adult survivors of childhood cancer are undertreated for CVD risk factors compared with the general population.
Read More
Dr Constantine Tam Discusses Impact of Public Funding for BTK Inhibitor Use in R/R CLL
June 10th 2022Constantine S. Tam, MBBS, MD, consulting hematologist and associate professor, Peter MacCallum Cancer Centre, explains findings of his abstract at EHA2022 showing the impact of Australia’s pharmaceuticals benefit scheme on the rise of Bruton tyrosine kinase (BTK) inhibitor prescriptions for the treatment of relapsed/refractory chronic lymphocytic leukemia (R/R CLL), as well as reasons behind the decrease in fludarabine, cyclophosphamide, and rituximab combination therapy usage for first-line CLL.
Watch